large-artery atherosclerosis, vs

large-artery atherosclerosis, vs. titers scored better on TICS-m compared to seronegative patients (crude = 2.33[95%CI = 0.76 to 3.91]; adjusted = 2.47[95%CI = 0.75 to 4.19]); in contrast, patients with high titers scored lower on TICS-m (crude = 2.82[95%CI = 4.90 to 0.74], adjusted = 2.96[95%CI Adamts1 = 5.13 to 0.80]), compared to seronegative patients. == Conclusion == In our study, NMDAR1-abdominal muscles seropositivity did not impact CF over 3 years after a first moderate to moderate ischemic stroke. CF differed according to NMDAR1-abdominal muscles serum titer, with patients with high NMDAR1-abdominal muscles titers using a less favorable cognitive end result compared to seronegative patients. == Supplementary Information == The online version contains supplementary material available at 10.1007/s00415-022-11203-x. Keywords:Stroke, Ischemia, Epidemiology, Antibodies, Cognitive dysfunction == Introduction and background == Cognitive impairment is usually frequent after stroke and up to one-third of all stroke patients develop incident post-stroke dementia.[1,2] N-methyl-D-aspartate (NMDA) receptors are types of ionotropic glutamate receptors, sensibly regulating mechanisms of neuroplasticity, memory and cognition; however, they also play an important role in excitotoxic damage.[3] Anti-NMDA (N-methyl-D-aspartate)-receptor GluN1 (also NR1) antibodies (NMDAR1-abs) SPL-707 were first explained in the context of a severe neuropsychiatric disease, today known as anti-NMDA-receptor encephalitis.[4] Serum NMDAR1-abs, primarily of the IgA and IgM isotypes, have been observed in about 10% of the apparently healthy and differently diseased populations.[5,6] Some studies found associations between seropositivity and cognitive impairment.[7,8] Previously, NMDAR1-abs seropositivity was proposed to exert beneficial effects in stroke pathology, supported by smaller infarct lesion growth in NMDAR1-abs seropositive patients in a large study of ischemic stroke patients.[9,10] We hypothesized that NMDAR1-abs modify NMDAR function leading to altered cognitive outcome in seropositive patients following a stroke event. Therefore, we aimed to study the effects of NMDAR1-abdominal muscles seropositivity on cognitive end result in the long term after stroke in a large cohort of first-ever stroke patients. == Materials and methods SPL-707 == SPL-707 == The PROSpective Cohort with Incident Stroke-Berlin (PROSCIS-B) study == The PROSCISB study (ClinicalTrials.gov identifier:NCT01363856) is a prospective observational hospital-based cohort study, which recruited patients at three tertiary university hospital stroke units of the CharitUniversittsmedizin Berlin with first-ever stroke according to Who also criteria,[11] to study stroke secondary risks. Patients presenting with brain tumor or brain metastasis of a tumor of other origin, or patients participating in an intervention study, were excluded. Furthermore, we only included patients presenting without moderate to severe aphasia due to ethical regulations. Details on the study design have been explained previously.[12,13] For a detailed baseline characterization, an extensive clinical and technical examination was performed within 7 days after the acute event including blood sampling for laboratory steps. Magnetic resonance imaging (MRI) data were additionally collected retrospectively from clinical records and therefore did not follow standardized protocols. Patients were followed up annually by telephone interviews or postal mail contact assessing, i.a., cognitive function and functional end result up to three years after the index event. For this investigation, only patients with mild-to-moderate ischemic stroke events (National Institutes of Health Stroke Level [NIHSS] < 16) were included, as we counted very few cases with severe strokes (NIHSS > 15,n= 6). == Assessment of anti-NMDA-receptor antibodies == Serum blood samples were obtained from patients within 7 days after stroke and stored at 80 C until they were first-ever thawed for antibody measurements. NMDAR1-abdominal muscles IgM, IgA and IgG were measured with cell-based assays by the Euroimmun laboratory in Luebeck, Germany. Briefly, HEK293 cells were transfected with GluN1 subunits of NMDA receptors to bind antibodies of the IgM, IgA and IgG isotype from patient serum. Fluorescein isothiocyanate anti-human IgM, IgA and IgG were secondarily administered to manually obtain staining with fluorescence microscopy. The assessors experienced no insight into individual data. Details on the procedure have been explained elsewhere.[4,14] Titer levels started from a dilution of 1 1:10, which defined seropositivity in our study. For sub-groups, we a priori defined titers of 1 1:10 to 1 1:100 as low.